Targeting Non-coding RNAs for the Development of Cancer Therapeutic Approaches
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 21
Special Issue Editors
Interests: molecular mechanisms of anti-tumor drugs; drug delivery; miRNA; siRNA; hepatocellular carcinoma
Special Issues, Collections and Topics in MDPI journals
Interests: molecular mechanisms of antitumor drugs; miRNA; siRNA; zebrafish model of human diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer remains a global health challenge, representing the second leading cause of death worldwide. Thus, novel therapeutic strategies are urgently required. In this regard, non-coding RNAs (ncRNAs) constitute an attractive class of biological molecules with great therapeutic and monitoring potential. ncRNAs can be subdivided in short non-coding RNAs (sncRNAs) when containing less than 200 nucleotides and long non-coding RNAs (lncRNA) when containing more than 200 nt. sncRNA includes micro RNAs (miRNA), small interfering RNA (siRNA), piwi-interacting RNA (piRNA), small nuclear RNA (snRNA), small nucleolar RNAs (snoRNAs), extracellular RNA (exRNA), and small Cajal body-specific RNAs (scaRNAs); lncRNAs encompass linear lncRNA, circular lncRNA, long intergenic non-coding RNA, enhancer-derived RNA, transcribed ultra-conserved RNA, and natural antisense transcript. ncRNA regulates gene expression via an intricated and redundant network of interactions; this results, among others, in oncogenic or anti-oncogenic effects in the cells. Since the discovery of the first ncRNA in 2001, much evidence has emerged in the literature about their potential usefulness in both cancer therapy and monitoring. So far, however, the partial understanding of the great biological complexity governing ncRNAs has slowed down practical use in the clinic. Despite this, there is confidence that the deepening of the knowledge of ncRNA biology achieved via further extensive research can result in the identification of valuable therapeutic and monitoring molecules for many different types of human cancers.
This Special Issue of IJMS aims to provide a comprehensive overview of the latest research on ncRNAs from the more basic to more applicative investigations such as tumor therapeutic targets and tumor markers.
Prof. Dr. Gabriele Grassi
Dr. Federica Tonon
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- short/long non-coding RNAs
- therapy
- diagnosis
- tumor markers
- mechanism of action
